Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

Inclusion Criteria

• •The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH).
• •One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital.
• •Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services.
• •breast cancer diagnosis
• •no clinical evidence of metastatic disease
• •able for curative treatment with surgery with or without oncological treatment.
• •prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last).
• •breast cancer diagnosis (as per self-reported) irrespective of stage and treatment.
• •proostate cancer diagnosis
• •no clinical evidence of metastatic disease
• •able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination).
• •prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment.